Drug intelligence / Profile preview

KW-027

Development stage: Preclinical
Lead developer: Kawin Technology
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

KW-027 is an investigational monoclonal antibody developed by Kawin Technology for the treatment of chronic Hepatitis B virus (HBV) infection. It is part of Kawin's comprehensive HBV pipeline, which also includes siRNA (KW-026) and peginterferon (KW-021) candidates, aimed at achieving a functional cure for the disease. KW-027 is designed to target and neutralize HBV-related antigens, likely the Hepatitis B surface antigen (HBsAg), to facilitate viral clearance and restore the host's immune response. The drug is currently in the early stages of development.

Other names: KW-027 AntibodyKW027 AntibodyKW 027 Antibody

Targets

HBsAg (Hepatitis B surface antigen)

Beyond the preview

Go deeper on KW-027.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KW-027.

Explore the full profile